GLP-1semaglutidechronic kidney diseasetype 2 diabetesnature medicine

Semaglutide trial misses MRI oxygenation endpoints in diabetic kidney disease

Secondary imaging and transcriptomic measures pointed to lower renal artery resistive index and glomerular endothelial changes in the 106-participant study.

By Maren Holt · Senior Reporter, GLP-1

Sep 30 20:00 ETSource: Nature medicine

The wire

01In a 52-week randomized trial of subcutaneous semaglutide 1 mg weekly versus placebo in 106 people with type 2 diabetes and chronic kidney disease, coprimary MRI outcomes of oxygenation, perfusion and T1 inflammation were unchanged.
02Clinicians following semaglutide's kidney benefit get mechanistic detail: reduced renal artery resistive index, stabilized apparent diffusion coefficient suggesting less fibrosis progression, and effects on glomerular endothelial cells.
03Biopsy, single-nucleus and spatial transcriptomic substudies were small (n=33, 22 and 13), and the primary imaging endpoints were negative, so mechanism remains inferred rather than established.

From the source

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
Nature medicine · 2026 Oct 1 · Tuttle KR, Bjornstad P, Smith C et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42823485/